Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Once given ’no respect,’ cells’ tiny RNAS take driver’s seat

09.06.2005


Ribonucleic acid, or RNA, has long been thought to be important only to translate a gene’s DNA into the proteins that are cells’ workhorses. But new evidence shows that tiny bits of RNA not used to make proteins actually play central roles in normal biology and in the development of cancers.

"Scientists have known for a few years that production of these tiny RNAs, known as microRNAs, is only supposed to happen at certain times and in certain tissues, but no one had been able to identify what controlled the timing," says Joshua Mendell, M.D., Ph.D., assistant professor in the McKusick-Nathans Institute of Genetic Medicine. "We’ve identified the first such controller, a well-studied protein called Myc. Our discovery fits in quite well with the two other labs’ studies on the involvement of microRNAs in cancer." The work from investigators at Johns Hopkins is one of three papers on microRNAs in the June 9 issue of Nature.

Identified only a few years ago, microRNAs’ best-known function is to control the extent to which other genes can be used to make proteins, by binding to and interfering with genes’ protein building-instructions. The microRNAs play roles in cell division, cell specialization and cell death in worms and flies and are off-kilter in human cancers, but the Myc protein is the first factor identified that controls the production of microRNAs.



Myc (pronounced "mick") is already known to regulate about 10 percent to 15 percent of the genes in the human genome, controlling the extent to which they are used to make proteins. Myc also is faulty and overactive in many human cancer cells, although exactly how it contributes to cancer is unclear.

Given Myc’s regulatory role and its involvement in cancer, the Hopkins researchers tested human cells to see whether changes in the amount of Myc affected levels of any of the more than 200 known microRNAs. Through these experiments and others, they discovered that Myc directly controls the gene for a set of six microRNAs in a region of chromosome 13 that is already tied to development of human lymphoma.

MicroRNAs are made by the same cellular machinery that makes other forms of RNA -- like the messenger RNA used to build proteins. However, microRNAs are immediately processed by cellular machinery that deals with what is known as RNA interference -- a biological phenomenon that specifically prevents RNA from being used to make proteins.

Accompanying the Hopkins paper are two reports looking specifically at microRNAs in cancer -- one in humans, one in mice. One report shows that human tumors’ microRNA "fingerprints" -- patterns showing which of the more than 200 known microRNAs are more or less abundant than normal -- identify the tumors’ tissue of origin much better than other tests. The other paper shows that over-expression of chromosome 13’s microRNAs dramatically increases the risk of cancer in mice predisposed to cancer because of a faulty Myc gene.

"We’ve found that there’s complex crosstalk between Myc, the microRNAs and the genes that both control," says Mendell. "This complex system, if disturbed, has the potential to very potently drive cell growth and cancerous proliferation."

Among the genes Myc controls is one called E2F1, which, like Myc, also controls the expression of genes. One of the genes controlled by E2F1 just happens to be the gene for Myc.

"This establishes a feedback loop," says Kathryn O’Donnell, Ph.D., who conducted much of the work as a graduate student in the Human Genetics Program. "Because both Myc and E2F1 increase the expression of genes that increase cell growth, the pair could be quite dangerous if they simply fed off each other."

But the researchers also discovered that two of the six microRNAs controlled by Myc actually reduce cells’ ability to use E2F1’s protein-building instructions. Essentially, these microRNAs act as a "brake" to slow E2F1’s growth-promoting effects.

"So the Myc protein ’turns up’ the genes for E2F1 and the microRNAs, but the microRNAs reduce the amount of E2F1 protein that can be made, fine-tuning Myc’s effects, perhaps," says Mendell. "We chose to look for interactions with E2F1 specifically, but there are bound to be many, many more genes that these microRNAs regulate."

"Whether too much or too little of these or other microRNAs is a good thing or a bad thing -- whether it would contribute to or help prevent cancer -- depends on their targets in the cell," adds Myc specialist Chi Dang, M.D., Ph.D., the Johns Hopkins Family Professor in Oncology Research and a professor of medicine in the McKusick-Nathans Institute and the Johns Hopkins Kimmel Cancer Center. "Slowing E2F1 production would seem to be a good thing because doing so would slow cell growth, but that might not be the case for other genes controlled by these microRNAs."

Encoded for by genes’ DNA, just like other RNA, microRNAs start out more than 1,000 building blocks long. Because they are able to fold back on themselves, they form double-stranded RNA, rather than the single strand characteristic of messenger RNA. As a result, the cell breaks the RNA into pieces. All sections except the microRNAs, just 21 to 23 building blocks long, is discarded.

The microRNAs can bind to single-strand messenger RNAs of the right sequence, which at the very least interferes with their ability to be read to make proteins and sometimes leads to the RNAs’ destruction.

"Now we’re figuring out the functions of these Myc-controlled microRNAs, other genes they regulate, and how else they might be involved in Myc-mediated initiation of cancer," says O’Donnell, who conducted her graduate work in Dang’s laboratory.

Joanna Downer | EurekAlert!
Further information:
http://www.jhmi.edu
http://www.nature.com/nature

More articles from Life Sciences:

nachricht A Map of the Cell’s Power Station
18.08.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht On the way to developing a new active ingredient against chronic infections
21.08.2017 | Deutsches Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Nagoya physicists resolve long-standing mystery of structure-less transition

21.08.2017 | Materials Sciences

Chronic stress induces fatal organ dysfunctions via a new neural circuit

21.08.2017 | Health and Medicine

Scientists from the MSU studied new liquid-crystalline photochrom

21.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>